Argenica Therapeutics (ASX:AGN) secures INN for lead neuroprotective candidate

Argenica Therapeutics (ASX:AGN) has announced that the World Health Organisation (WHO) has confirmed “xaranetide” as the International Nonproprietary Name (INN) for its lead drug candidate, ARG-007.

The confirmation was made with no objections noted, and the public consultation process has concluded.

Highlights

• WHO confirms xaranetide as proposed INN for ARG-007 with no objections
• Public consultation process concluded; publication as recommended INN expected shortly
• Xaranetide will be used in regulatory, scientific, and medical communications
• Announcement approved for release by the Board of Argenica

The WHO INN Programme evaluates proposed names through a formal review process before publication in the WHO List of Proposed INNs.

Following a public consultation period and consideration of any objections, the proposed name reaches the status of a recommended INN, and for xaranetide the consultation process has concluded with no objections, with publication in the WHO List of Recommended INNs expected shortly.

The INN xaranetide will become the recognised generic name for ARG-007 across regulatory, scientific, and medical communities globally, and the company has stated it will begin to include xaranetide in its communications.

Argenica Managing Director Dr Liz Dallimore said:

“The proposal of xaranetide as the INN for ARG-007 represents an important milestone in the maturation of our lead clinical asset. Establishing a globally recognised generic name is a key step as we continue advancing ARG-007 through clinical development and engage with regulators, investigators and future commercial partners worldwide,”

Argenica Therapeutics is a clinical-stage biotechnology company developing neuroprotective therapeutics to improve outcomes for patients following stroke and other acute neurological injuries.

The company’s lead drug candidate, xaranetide (ARG-007), is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischemic event.

Xaranetide is currently the company’s principal clinical asset, and its development forms the central focus of Argenica’s research efforts.

The company continues to advance ARG-007 through its defined clinical pathway while maintaining communications with regulators, investigators, and scientific collaborators.

Inclusion of the INN in these communications ensures consistency in terminology across clinical and regulatory documents worldwide.